Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  News  >  Companies  >  All News

News : Companies
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance ProfessionalsCalendarSectors

Cryoport : With More Than 200 Cell and Gene INDs on File with FDA by 2020, Challenges Lie Ahead on Path to Approval

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/25/2019 | 03:36pm EDT

'By 2025, we predict that the FDA will be approving 10 to 20 cell and gene therapy products a year based on an assessment of the current pipeline and the clinical success rates of these products.' - Scott Gottlieb, Former FDA Commissioner

With the cell and gene therapy boom, and five to 10 percentprojected approval rates, what challenges lie ahead and what do you need to know now to forge a successful path to approval?

One major challenge is the integrity of product from raw material to final product: Contamination, environmental changes, tracking discrepancies, lack of information, lack of accurate information and other inconsistencies during transport can compromise the integrity of patient, donor and final product. The potential consequences are ineffective final therapies administered to patients - a resultwe deem unacceptable.

ISO/TC 276 U.S. will require enhanced traceabilityand regulatory requirements in support of logistics distribution due to the fragile aspect of drug product and disproportionate risk of improper cold chain management on the viability of therapies.

With the many touchpoints from starter material to final therapies, the risks are great. Cryoport created Chain of Complianceto implement traceability and risk mitigation throughout the entire transportationprocess.

  • Engineering of equipment used
  • 100% requalificationand documentationof equipment and components before and aftereveryshipment
  • Nearreal-time monitoring and traceability throughout transit, not just pickup and delivery location and time
  • Easily accessible reports to prove appropriate temperatures were maintainedthroughout transit
  • Validated cleaning processes
  • Data integration to follow the journey from start to finish
  • Commercial scalability competencies to continue your success after approval

We created Chain of Complianceto stay ahead of the changing landscape, address foreseen and unforeseen challenges to ultimately provide unmatched support for viable, safe, and effective cell and gene therapies that positively impact and save lives.

Learn More

Disclaimer

Cryoport Inc. published this content on 25 June 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 June 2019 19:35:02 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news "Companies"
04:22aAcron Group's Mineral Fertiliser Output Up 4% in H1 2019
GL
04:20aAAP IMPLANTATE : is granted European patent for its innovative resorbable magnesium implant technology
EQ
04:20aELANIX BIOTECHNOLOGIES AG : Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQ
04:20aSAP SE : Notification and public disclosure of transactions by persons
EQ
04:17aTED BAKER : shares soar on private equity buyout reports
RE
04:16aNEWS HIGHLIGHTS : Top Energy News of the Day
DJ
04:05aInvitation to Oerlikon's Q2 / H1 2019 conference call
TE
04:04aEMAAR PROPERTIES : Beijing Daxing International Airport in deal on $11 billion project - WAM
RE
04:02aAMERISUR RESOURCES : Form 8.5 (EPT/RI) - Amerisur Resources plc
AQ
04:01aM REAL OYJ A SHARE : Invitation to conference call and webcast presentation of Metsä Board's Half-Year Financial Report for January-June 2019 on 1 August 2019
AQ
Latest news "Companies"
Advertisement